AU2011226992B2 - Immunostimulatory and vaccine compositions - Google Patents

Immunostimulatory and vaccine compositions Download PDF

Info

Publication number
AU2011226992B2
AU2011226992B2 AU2011226992A AU2011226992A AU2011226992B2 AU 2011226992 B2 AU2011226992 B2 AU 2011226992B2 AU 2011226992 A AU2011226992 A AU 2011226992A AU 2011226992 A AU2011226992 A AU 2011226992A AU 2011226992 B2 AU2011226992 B2 AU 2011226992B2
Authority
AU
Australia
Prior art keywords
composition
kda
mannan
size distribution
ants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011226992A
Other languages
English (en)
Other versions
AU2011226992A1 (en
Inventor
Geoffrey Alan Pietersz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ascend Biopharmaceuticals Pty Ltd
Original Assignee
Ascend Biopharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010901997A external-priority patent/AU2010901997A0/en
Application filed by Ascend Biopharmaceuticals Pty Ltd filed Critical Ascend Biopharmaceuticals Pty Ltd
Priority to AU2011226992A priority Critical patent/AU2011226992B2/en
Publication of AU2011226992A1 publication Critical patent/AU2011226992A1/en
Priority to AU2012200183A priority patent/AU2012200183B2/en
Application granted granted Critical
Publication of AU2011226992B2 publication Critical patent/AU2011226992B2/en
Assigned to ASCEND BIOPHARMACEUTICALS PTY LTD reassignment ASCEND BIOPHARMACEUTICALS PTY LTD Request for Assignment Assignors: 4G VACCINES PTY LTD
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2011226992A 2010-05-10 2011-05-10 Immunostimulatory and vaccine compositions Ceased AU2011226992B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2011226992A AU2011226992B2 (en) 2010-05-10 2011-05-10 Immunostimulatory and vaccine compositions
AU2012200183A AU2012200183B2 (en) 2010-05-10 2012-01-12 Immunostimulatory and vaccine compositions

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US33308610P 2010-05-10 2010-05-10
AU2010901997 2010-05-10
US61/333,086 2010-05-10
AU2010901997A AU2010901997A0 (en) 2010-05-10 Immunostimulatory and vaccine compositions
AU2010904060A AU2010904060A0 (en) 2010-09-09 Immunostimulatory and vaccine compositions
AU2010904060 2010-09-09
PCT/AU2011/000542 WO2011140595A2 (en) 2010-05-10 2011-05-10 Immunostimulatory and vaccine compositions
AU2011226992A AU2011226992B2 (en) 2010-05-10 2011-05-10 Immunostimulatory and vaccine compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012200183A Division AU2012200183B2 (en) 2010-05-10 2012-01-12 Immunostimulatory and vaccine compositions

Publications (2)

Publication Number Publication Date
AU2011226992A1 AU2011226992A1 (en) 2011-11-24
AU2011226992B2 true AU2011226992B2 (en) 2012-03-22

Family

ID=44914748

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011226992A Ceased AU2011226992B2 (en) 2010-05-10 2011-05-10 Immunostimulatory and vaccine compositions

Country Status (9)

Country Link
US (1) US9597392B2 (https=)
EP (1) EP2574170A4 (https=)
JP (1) JP6096111B2 (https=)
CN (1) CN102985095B (https=)
AU (1) AU2011226992B2 (https=)
BR (1) BR112012028893A2 (https=)
CA (1) CA2798856C (https=)
RU (1) RU2578420C2 (https=)
WO (1) WO2011140595A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2725450T3 (es) 2007-07-02 2019-09-24 Etubics Corp Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
IN2014CN04251A (https=) * 2011-11-09 2015-07-17 Ascend Biopharmaceuticals Ltd
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
ES2503516B1 (es) * 2013-04-03 2015-09-09 Inmunotek, S.L. Complejo inmunogénico para vacunación y método de obtención
CA2973109A1 (en) 2015-01-09 2016-07-14 Etubics Corporation Methods and compositions for ebola virus vaccination
KR102193635B1 (ko) 2015-01-09 2020-12-21 이투빅스 코포레이션 복합 면역요법을 위한 방법 및 조성물
WO2016172249A1 (en) * 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy
JP7084881B2 (ja) 2016-06-22 2022-06-15 アルカームス インコーポレーテッド Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法
FI3833378T3 (fi) 2018-08-06 2025-06-16 Nielsen Biosciences Inc Syylien hoito
US11197910B1 (en) * 2020-08-19 2021-12-14 Vitruviae LLC Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases
EP4304606A4 (en) * 2021-03-12 2025-08-20 Childrens Medical Center POLYSACCHARIDE-BASED ADJUVANTS FOR VIRUS VACCINES
CN113616799B (zh) * 2021-07-13 2023-08-29 中国科学院长春应用化学研究所 一种疫苗载体、其制备方法及应用
JPWO2024117232A1 (https=) * 2022-11-30 2024-06-06

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002003999A1 (en) * 2000-07-10 2002-01-17 The University Of Missisippi High molecular weight polysaccharide fraction from aloe vera with immunostimulatory activity
US20020031524A1 (en) * 2000-08-10 2002-03-14 Kralovec Jaroslav A. Chlorella preparations exhibiting immunomodulating properties
WO2005044861A1 (en) * 2003-10-31 2005-05-19 Wyeth Holdings Corporation Polysaccharides of helicobacter pylori

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362951A (en) 1965-12-21 1968-01-09 Farkas Alexander Polysaccharide product derived from the juice of the aloe plant and methods for preparing same
US4735935A (en) 1985-12-17 1988-04-05 Carrington Laboratories, Inc. Process for preparation of aloe products products, produced thereby and compositions thereof
US5308838A (en) 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
US4861761A (en) 1984-06-28 1989-08-29 Dr. Madis Laboratories, Inc. Aloeferon isolation, manufacturing and its applications
FR2573656B1 (fr) * 1984-11-29 1987-02-27 Sanofi Sa Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose
EP0823438A3 (en) 1987-01-07 1999-09-15 Imperial Cancer Research Technology Limited Human mucin cone protein: peptide fragments and antibodies thereto, and uses thereof in diagnostic and therapeutic methods
US6222020B1 (en) 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
ATE475668T1 (de) 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
US5939400A (en) 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
US6110898A (en) 1996-05-24 2000-08-29 University Of Maryland, Baltimore DNA vaccines for eliciting a mucosal immune response
US5824659A (en) 1996-09-04 1998-10-20 Board Of Regents, The University Of Texas System Cytoprotective oligosaccharide from Aloe preventing damage to the skin immune system by UV radiation
ATE341339T1 (de) 1996-12-20 2006-10-15 Merck & Co Inc Zusammensetzungen von rekombinanten papillomavirus vakzinen
ES2357960T3 (es) 1997-05-08 2011-05-04 Oncothyreon Inc. Procedimiento para generar células t activadas y células presentadoras de antígenos pulsadas con antígenos.
CA2329897A1 (en) 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
DE19917195B4 (de) 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
JP2003510094A (ja) 1999-09-08 2003-03-18 トランジェーヌ、ソシエテ、アノニム Ｍｕｃ−１由来のペプチド
EP1257565A4 (en) 2000-02-01 2005-04-06 Austin Research Inst DERIVED FROM MUCIN-1 ANTIGENE AND ITS USE IN IMMUNOTHERAPY
AUPQ797700A0 (en) * 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
WO2008037033A1 (en) * 2006-09-29 2008-04-03 The Macfarlane Burnet Institute For Medical Research And Public Health Limited Flu vaccine admixture of mannan and flu antigen
NZ538812A (en) 2002-08-15 2009-02-28 3M Innovative Properties Co Immunostimulatory compositions and methods of stimulating an immune response
AU2003256912A1 (en) 2002-08-16 2004-03-03 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
EP1697515A4 (en) * 2003-11-12 2008-02-06 Austin Research Inst DNA CARRIER CONJUGATE
US20060084629A1 (en) 2004-10-15 2006-04-20 Alvin Needleman Immune system activating formula composed of selected long chain polysaccharides from natural sources
JP2006241023A (ja) * 2005-03-01 2006-09-14 Asahi Breweries Ltd 消化管組織における抗菌ペプチドの発現誘導または産生促進剤
JP2006241020A (ja) * 2005-03-01 2006-09-14 Asahi Breweries Ltd 免疫系賦活剤
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
JP2009544291A (ja) 2006-07-25 2009-12-17 フォージー ヴァクシンズ ピーティーワイ エルーティーディー ムチン１（ｍｕｃ１）ｔ細胞エピトープ由来ペプチド含有癌ワクチン
AU2007300543A1 (en) 2006-09-26 2008-04-03 Alexion Pharmaceuticals, Inc. Compositions and methods for enhancing an adjuvant
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002003999A1 (en) * 2000-07-10 2002-01-17 The University Of Missisippi High molecular weight polysaccharide fraction from aloe vera with immunostimulatory activity
US20020031524A1 (en) * 2000-08-10 2002-03-14 Kralovec Jaroslav A. Chlorella preparations exhibiting immunomodulating properties
WO2005044861A1 (en) * 2003-10-31 2005-05-19 Wyeth Holdings Corporation Polysaccharides of helicobacter pylori

Also Published As

Publication number Publication date
EP2574170A4 (en) 2013-11-20
JP2013527854A (ja) 2013-07-04
CA2798856C (en) 2019-04-23
BR112012028893A2 (pt) 2017-12-12
US20130251741A1 (en) 2013-09-26
AU2011226992A1 (en) 2011-11-24
JP6096111B2 (ja) 2017-03-15
RU2578420C2 (ru) 2016-03-27
EP2574170A2 (en) 2013-04-03
WO2011140595A2 (en) 2011-11-17
US9597392B2 (en) 2017-03-21
CN102985095B (zh) 2016-05-18
WO2011140595A3 (en) 2012-01-05
RU2012152952A (ru) 2014-06-20
CA2798856A1 (en) 2011-11-17
CN102985095A (zh) 2013-03-20

Similar Documents

Publication Publication Date Title
AU2011226992B2 (en) Immunostimulatory and vaccine compositions
AU2012334825B2 (en) Immunomodulatory conjugates
Zhu et al. Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity
Wang et al. Gold nanoparticles conjugating recombinant influenza hemagglutinin trimers and flagellin enhanced mucosal cellular immunity
Hanson et al. Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants
Minigo et al. Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy
JP4184433B2 (ja) 免疫調節のための医薬組成物
EP4262876B1 (en) Covalently modified antigens for improved immune response and/or stability
JP2000503853A (ja) 抗原特異的免疫応答を生起させる遺伝子発現ベクターおよびその使用方法
Akache et al. Adjuvants: engineering protective immune responses in human and veterinary vaccines
US20250360202A1 (en) HERPES ZOSTER mRNA VACCINE, PREPARATION METHOD THEREFOR, AND USE THEREOF
Liu et al. Synthetic MUC1 breast cancer vaccine containing a Toll-like receptor 7 agonist exerts antitumor effects
JP6165182B2 (ja) 免疫アジュバントとしてのグリコシル化により改変された四官能性非イオン性両親媒性ブロックコポリマーの使用
KR101736487B1 (ko) 신규 면역아쥬반트 화합물 및 이의 용도
KR20140099828A (ko) 점막 투여용 백신 조성물
Tang et al. Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses
AU2012200183B2 (en) Immunostimulatory and vaccine compositions
Xu et al. A Recombinant lipidated Receptor-binding domain Is a Promising Self-Adjuvanting Antigen for Mucosal Vaccine
WO2008151389A1 (en) Chemically modified macromolecules
Patel et al. Cationic nanoparticles for delivery of CpG oligodeoxynucleotide and ovalbumin: In vitro and in vivo assessment
KR20070036020A (ko) 세포독성 반응의 어쥬번트 유도물질로서 프로테오리포솜 및그 유도체류와 수득된 제형
WO2023013785A1 (ja) Ｓｎａｒｅを活用した核酸構築物
WO2023211279A1 (en) Adjuvant combinations for neopeptide vaccines
BR112016020373B1 (pt) Composição, e, método para preparação de uma composição

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ASCEND BIOPHARMACEUTICALS PTY LTD

Free format text: FORMER OWNER WAS: 4G VACCINES PTY LTD

MK14 Patent ceased section 143(a) (annual fees not paid) or expired